Sharekhan

Caplin Point Laboratories Ltd

Tue 6/05/2025,15:43:57 | NSE : CAPLIPOINT

₹ 1852.70-53.70 (-2.82%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1899.50

Previous Close

₹ 1906.40

Volume

90326

Mkt Cap ( Rs. Cr)

₹14082.69

High

₹ 1902.40

Low

₹ 1830.10

52 Week High

₹ 2641.00

52 Week Low

₹ 1225.00

Book Value Per Share

₹ 334.49

Dividend Yield

0.26

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Caplin Point Laboratories Ltd

Your Vote -

Buy

76.21%

Hold

4.37%

Sell

19.42%

76.21%

206 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

1852.70

462

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

462

Option Chain

Analyzes market sentiment, predicts Caplin Point Laboratories Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers caplin point laboratories ltd stock attention, sentiment.

  • Caplin Point Lab - Press Release

    23 Apr 2025, 10:51AM Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated April 23, 2025, titled ""Press Release regarding receipt o
  • Caplin Point Lab - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    23 Apr 2025, 10:45AM Press Release regarding receipt of USFDA Approval is attached herewith.
  • Caplin Point Lab - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    21 Apr 2025, 6:59PM CAPLIN POINT LABORATORIES LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Tr
  • Caplin Point Lab - Cessation

    21 Apr 2025, 6:59PM Caplin Point Laboratories Limited has informed the Exchange regarding Cessation of Mr. Thiagaraja Manikandan as Chief Transformation & Digital Office
  • Caplin Point Lab - Announcement under Regulation 30 (LODR)-Cessation

    21 Apr 2025, 6:38PM The details of resignation of Senior Management Personnel is attached herewith.
  • Caplin Point Lab has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    18 Apr 2025, 8:30PM As of March 2025, 70.56% is owned by Indian Promoters and 29.44% by Public. <p align=justify> Institutional holds 7.73% (Insurance Companies 0.20%) an
  • Caplin Point Lab - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    3 Apr 2025, 6:06PM Caplin Point Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Caplin Point Lab - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    3 Apr 2025, 5:58PM Compliance Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2025 is enclosed.
  • Caplin Point Lab - General Updates

    2 Apr 2025, 4:13PM Caplin Point Laboratories Limited has informed the Exchange about General Updates that the Board of Directors of Caplin Point Far East Limited, Hong K
  • Caplin Point Lab - Announcement under Regulation 30 (LODR)-Acquisition

    2 Apr 2025, 3:40PM Caplin Point Laboratories Limited informed that the Board of Directors of Caplin Point Far East Limited, Hong Kong, a material subsidiary of the Compa
  • Caplin Point Lab - Action(s) taken or orders passed

    29 Mar 2025, 6:43PM Caplin Point Laboratories Limited has informed the Exchange about Action(s) taken or orders passed. Enclosing a copy of cautionary e-mail received fro
  • Caplin Point Lab - Cautionary Letter From NSE And BSE On March 28, 2025

    29 Mar 2025, 6:32PM Enclosing a copy of cautionary e-mail received from National Stock Exchange of India Limited and BSE Limited with respect to the intimation of Schedul
  • Caplin Point Lab - Trading Window-XBRL

    25 Mar 2025, 4:54PM CAPLIN POINT LABORATORIES LIMITED has informed the Exchange about Closure of Trading Window
  • Caplin Point Lab - Trading Window

    25 Mar 2025, 4:49PM Caplin Point Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Reg
  • Caplin Point Lab - Press Release

    26 Feb 2025, 10:54AM Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated February 26, 2025, titled ""Press Release regarding receip
  • Caplin Point Lab - Analysts/Institutional Investor Meet/Con. Call Updates

    14 Feb 2025, 6:30PM Caplin Point Laboratories Limited has informed the Exchange about Transcript
  • Caplin Point Lab - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    14 Feb 2025, 6:25PM The link for the transcript of the earnings call w.r.t financial performance of the company for quarter and nine months ended 31-12-2024 is enclosed.
  • Caplin Point Lab - Copy of Newspaper Publication

    8 Feb 2025, 4:49PM Caplin Point Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
  • Caplin Point Lab - Analysts/Institutional Investor Meet/Con. Call Updates

    7 Feb 2025, 7:24PM Caplin Point Laboratories Limited has informed the Exchange about Link of Recording
  • Caplin Point Lab - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    7 Feb 2025, 7:15PM The web link for the audio recording of the Earnings call Q3 2024-25 held today i.e., Friday, February 02, 2025 at 17:00 hrs is enclosed
  • Caplin Point Lab - Integrated Filing- Financial

    7 Feb 2025, 6:49PM Integrated Filing (Financial) for Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024
  • Caplin Point Lab - Integrated Filing (Financial)

    7 Feb 2025, 6:46PM Integrated Filing (Financial) for Unaudited Financial Results for the quarter and nine months ended December 31, 2024 is enclosed
  • Caplin Point Lab - Financial Result Updates

    7 Feb 2025, 3:24PM Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
  • Caplin Point Lab Q3 net profit up 34.73% at Rs 74.71 cr

    7 Feb 2025, 1:42PM The company reported standalone net profit of Rs 74.71 crore for the quarter ended December 31, 2024 as compared to Rs 55.45 crore in the same period
  • Caplin Point Lab - Outcome of Board Meeting

    7 Feb 2025, 1:23PM Caplin Point Laboratories Limited has informed the Exchange regarding Board meeting held on February 07, 2025.
  • Caplin Point Lab - Board Meeting Outcome for Board Meeting Outcome Of The Financial Results For The Quarter Ended December 31

    7 Feb 2025, 1:21PM Financial Results along with the Limited Review Report, Press Release and Investor PPT for the Quarter Ended December 31, 2024 is enclosed
  • Caplin Point Lab - Financial Results For The Quarter Ended December 31, 2024

    7 Feb 2025, 1:16PM Financial Results along with the Limited Review Report, Press Release and Investor PPT for the quarter ended December 31, 2024 is enclosed
  • Caplin Point arm gets USFDA approval for Phytonadione Injectable Emulsion

    23 Apr 2025 , 11:07AM Phytonadione Injectable Emulsion used to treat bleeding or blood clotting problems caused by Vitamin K deficiency
  • Caplin Point Laboratories

    27 Feb 2025 , 11:43AM Company has been granted final approval from USFDA for its abbreviated New Drug Application (ANDA) Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution (Eye drops). It is a medication used in the treatment of Glaucoma.
  • Caplin Steriles gets USFDA approval for Procainamide Hydrochloride Injection

    5 Feb 2025 , 11:28AM Procainamide hydrochloride injection is used to treat certain Arrhythmia
  • Caplin Point arm gets USFDA nod for Levetiracetam

    17 Jan 2025 , 12:38PM Caplin Steriles gets USFDA nod for Levetiracetam in Sodium Chloride injection, Infusion bags
  • Caplin Point Laboratories

    7 Jan 2025 , 10:28AM The company's arm has received an Establishment Inspection Report from the US FDA with zero 483 observations for its Tamil Nadu manufacturing facility.
  • Caplin Point Laboratories

    19 Aug 2024 , 10:10AM ANVISA- Brazil conducted an inspection of Caplin Steriles’ injectable and ophthalmic manufacturing facility located at Gummidipoondi. The inspection was conducted between August 12th and 16th, 2024 and concluded with zero observations. (Positive)
  • Stock Update: Caplin Point

    9 Aug 2024 , 1:10PM Stock Update: Caplin Point - Decent quarter, Healthy outlook
  • Caplin Point Q1FY25 results

    7 Aug 2024 , 2:00PM Caplin Point Q1FY25 results – in-line set of numbers
  • Caplin Point Laboratories Ltd

    19 Jul 2024 , 1:45PM Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited has been granted final approval from the USFDA for its ANDA Ephedrine Sulfate injection USP, 50 mg/mL Single Dose vial, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) AKOVAZ, from Exela Pharma Sciences LLC. Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension occurring in the setting of anaesthesia. According to IQVIATM (IMS Health), Ephedrine Sulfate injection USP 50 mg/mL had US sales of approximately $36 million for the 12-month period ending May 2024. (Positive)
  • Caplin Steriles gets USFDA nod for Ephedrine Sulfate Injection USP

    19 Jul 2024 , 12:11PM Ephedrine Sulfate injection is use for the treatment of clinically important hypotension occurring in the setting of anaesthe
  • Caplin Point arm gets USFDA nod for ANDA

    24 May 2024 , 12:14PM Caplin Steriles gets USFDA nod for Phenylephrine hydrochloride Ophthalmic Solution USP
  • Caplin Points gets USFDA approval for ANDA Ofloxacin ophthalmic solution

    16 Apr 2024 , 10:54AM Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections
  • Stock Update: Caplin Point Laboratories

    15 Feb 2024 , 11:26AM Stock Update: Caplin Point Laboratories - Robust Q3; Growth momentum to continue
  • Caplin Point Laboratories

    9 Jan 2024 , 11:50AM Caplin Group of Companies signed a Memorandum of Understanding (MoU) with the Tamil Nadu Government during the Tamil Nadu Global Investors Meet, 2024. This MoU outlines Caplin Group's commitment to invest INR 700 Crores over a period of 5 years in diverse projects. This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited. Positive.
  • Caplin Point arm gets final USFDA nod for ANDA Ofloxacin Otic Solution

    8 Jan 2024 , 12:40PM Caplin Steriles gets USFDA approval for Ofloxacin Otic Solution
  • View Point update – Caplin Point Q2FY24 results review

    21 Nov 2023 , 11:43AM View Point update – Caplin Point Q2FY24 results review: Robust Q2; margins rise to record high
  • Caplin Steriles receives EIR from USFDA

    4 Sep 2023 , 12:42PM Caplin Point gets Establishment Inspection Report from USFDA for Chennai Unit
  • Caplin Point Labs

    3 Aug 2023 , 12:54PM The company has formed a step-down subsidiary named Caplin Steriles USA Inc. in the state of Delaware with an initial capital investment of USD 500,000. Once incorporated this company will be a related party of the company and its subsidiaries. It will be the marketing and distribution arm of the company in the US. It will help the company to front end for its wholly owned subsidiary Caplin Steriles Ltd. in the US for direct sales, marketing and distribution of the products manufactured by Caplin Steriles Ltd. Strongly positive as so far, the company is partnering with the US pharma companies to sell their products in the US. This can boost profitability further over medium – long term.
  • Caplin Point Laboratories

    21 Jul 2023 , 10:45AM Pfizer’s injectables plant which makes about 25% of sterile injectables for the US market suffered heavy damage from a tornado at North Carolina, which is expected to worsen the injectables shortage across the US, further. Positive for Caplin Point. We have a positive viewpoint on the stock with a potential upside of 8% left.
  • Caplin Point Laboratories

    13 Jun 2023 , 11:11AM Caplin Point has been granted approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Cisatracurium Besylate Injection USP, 10 mg/5 mL (2 mg/mL) and 200 mg/20 mL (10 mg/mL) Single-dose Vials; and 20 mg/10 mL (2 mg/mL) Multiple-dose Vials (Preserved)., a generic therapeutic equivalent version of (RLD), NIMBEX injection of AbbVie Inc. Cisatracurium Besylate Injection USP is a nondepolarizing skeletal neuromuscular blocker, indicated as an adjunct to general anaesthesia to facilitate tracheal intubation. According to IQVIATM (IMS Health), Cisatracurium Besylate Injection USP had US sales of approximately USD 35 million for the 12-month period ending December 2022. Positive read through
  • Caplin Steriles gets USFDA ANDA nod for Cisatracurium Besylate Injection

    12 Jun 2023 , 2:38PM Cisatracurium Besylate Injection is used as a muscle relaxant
  • Caplin Point Laboratories

    1 Jun 2023 , 11:23AM Caplin Point informs that the USFDA has completed its GMP and PAI inspection of Caplin Steriles Ltd. (a subsidiary of Caplin Point Labs) Sterile Injectable site at Gummidipoondi between May 22nd to 31st. At the end of the inspection, there were four observations by US FDA. These observations are procedural in nature and the corrective and preventive actions for these observations will be presented to the USFDA within the stipulated period. The observations made were not repeat observations or related to data integrity
  • Caplin Steriles gets USFDA nod for Ketorolac Tromethamine injection

    12 May 2023 , 12:10PM Caplin Point gets final USFDA ANDA nod for Ketorolac Tromethamine Injection that is used as a pain killer
  • Caplin Point Labs

    8 Mar 2023 , 11:32AM Caplin Steriles Ltd. has been granted final approval from the USFDA for its ANDA Thiamine Hydrochloride injection USP, 200 mg/2 mL (100 mg/L) Multi Dose vial, a generic therapeutic equivalent version of RLD, THIAMINE HYDROCHLORIDE injection of Fresenius Kabi USA LLC. It is effective for the treatment of Thiamine (Vitamin B1) deficiency or beriberi. According to IQVIA (IMS Health), Thiamine Hydrochloride Injection has US sales of approximately USD 38 million for LTM ending Sep 22. Positive read through for the stock.
  • Caplin Point gets USFDA nod for Thiamine Hydrochloride Injection

    8 Mar 2023 , 11:21AM Thiamine Hydrochloride Injection is effective in the treatment of Thiamine (Vitamin B1) deficiency or beriberi
  • Caplin Point Labs

    3 Mar 2023 , 12:01PM Caplin Point Labs has been granted final approval from the USFDA for its ANDA Rocuronium Bromide Injection, 10 mg/ml in 5 ml and 10 ml Multi Dose vials, a generic therapeutic equivalent version (RLD) of ZEMURON injection, of Organon USA Inc. The drug is a neuromuscular blocking agent indicated as an adjunct to general anaesthesia to facilitate both rapid sequence and routine tracheal intubation. According to IQVIA (IMS Health) Rocuronium Bromide Injection had sales of USD 53 million for the 12-month period ending September 2022. Positive read through. We have a positive view point on the stock.
  • Caplin Steriles gets USFDA nod for Rocuronium Bromide Injection

    3 Mar 2023 , 11:46AM Caplin Point gets USFDA nod for its abbreviated new drug application Rocuronium Bromide Injection
  • Caplin Point Laboratories

    14 Feb 2023 , 12:01PM Caplin Point Labs has been granted final approval from the USFDA for its ANDA Carboprost Tromethamine Injection USP 250 mcg/mL single dose vials, a generic therapeutic equivalent version (RLD), HEMABATE injection of Pfizer Inc. The injection has annual sales of USD 55 million for LTM ending Sep 22 as per IQVIA. Positive read through for the stock.
  • Viewpoint - Caplin Point Laboratories

    4 Feb 2022 , 12:38PM Viewpoint - Caplin Point Laboratories Q3FY22 Results - Strong Q3; robust outlook
  • Caplin Point Labs Q3FY22 results

    3 Feb 2022 , 4:18PM Caplin Point Labs Q3FY22 results: Strong quarter; results in line with estimates
  • Caplin Point Q3 net profit surges by 13.6% YoY

    3 Feb 2022 , 1:29PM Q3 earnings for the Quarter ended December 31, 2021
  • Viewpoint – Caplin Point Laboratories

    3 Dec 2021 , 9:53AM Viewpoint – Caplin Point Laboratories: On a strong growth path; Correction provides an opportunity
  • Viewpoint – Caplin Point Laboratories

    3 Dec 2021 , 9:50AM Viewpoint – Caplin Point Laboratories: On a strong growth path; Correction provides an opportunity
  • Caplin Point's cro amaris clinical completes USFDA audit with nil observations

    24 Sep 2021 , 12:55PM USFDA completes Caplin Point’s CRO division Amaris Clinicals' virtual audit with 'zero' observations
  • Caplin Point Laboratories

    8 Sep 2021 , 2:54PM Caplin Point Laboratories: Subsidiary company – Caplin Steriles has received approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Labetalol Hydrochloride Injection USP, 100 mg/20 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL). Labetalol Hydrochloride Injection USP is indicated for control of blood pressure in severe hypertension patients. As per IQVIA, the drug has reported US sales of approximately $6 mn for the 12 month ending June 2021. Given the sizeable market share the approval is positive
  • Caplin Point Lab gets USFDA nod for its Labetalol Hydrochloride Injection

    8 Sep 2021 , 12:25PM Caplin Steriles gets USFDA approval for Labetalol Hydrochloride Injection USP
  • Caplin Point Laboratories

    17 Aug 2021 , 3:08PM Caplin Point laboratories: The company’s subsidiary – Caplin Steriles has received an approval from the Brazil’s National Health Surveillance Agency - ANVISA for its sterile injectable manufacturing site near Chennai. The approval grants access to Caplin point to register and market its products in Brazil, which is one the largest markets in the LATAM region, hence the approval is a potential positive.
  • Caplin Steriles receives nod from Brazil's Anvisa

    17 Aug 2021 , 3:01PM The approval grants access to the company to register and market its products in Brazil
  • Caplin Point Laboratories (Viewpoint) : Result Update

    9 Aug 2021 , 2:03PM Caplin Point Laboratories (Viewpoint) : Result Update - strong quarter; promising outlook
  • Caplin Point Laboratories Q1FY22 results

    5 Aug 2021 , 2:44PM Caplin Point Laboratories Q1FY22 results: Strong quarter; operating performance in line with estimates
  • Caplin Point Laboratories

    14 Jul 2021 , 3:05PM Caplin Point Laboratories: Gets USFDA approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Injection USP strengths - 6 mg/0.5 mL (12 mg/mL) Single dose Vials. Sumatriptan Injection USP is indicated for treatment of acute migraine with or without aura, and treatment of acute cluster headache in adults. As per IQVIA the injection has reported US sales of $ 5 mn for the 12 month period ending March 2021 for Vial presentation. The approval is positive as it would add to the US sales growth, which constitute around 8% of overall Fy2021 turnover of the company.
  • Caplin Steriles gets USFDA approval for Sumatriptan Injection

    14 Jul 2021 , 1:55PM Sumatriptan Injection USP is indicated in adults for acute treatment of migraine with or without aura, and acute treatment of cluster headache
  • Caplin Point Laboratories – Viewpoint

    17 Jun 2021 , 10:54AM Caplin Point Laboratories – Viewpoint - Popping the growth pill
  • Caplin Steriles gets USFDA approval for Prochlorperazine Edisylate Injectionn FY 2003-04

    23 Apr 2021 , 11:47AM Caplin Point gets final nod from USFDA for its ANDA Prochlorperazine Edisylate Injection
  • Caplin Point surges on USFDA nod

    22 Apr 2021 , 11:13AM Caplin Steriles gets USFDA approval for Neostigmine Methylsulfate Injection
  • Caplin Steriles gets USFDA nod for Argatroban Injection

    22 Jan 2021 , 1:50PM Caplin Point Lab gets USFDA nod for Argatroban Injection, used as an anticoagulant for Prophylaxis
  • Caplin Steriles enters into a strategic partnership with Jamp Pharma group for Canada

    18 Jan 2021 , 11:29AM Caplin Point arm enters into a strategic partnership with JAMP Pharma for six injectable products in Canada
  • Caplin Point gets USFDA nod

    24 Dec 2020 , 1:38PM Approval is positive as it would help improve the US sales, which constitutes ~8% of FY2020 revenues.
  • Caplin Steriles to license five of its injectable ANDAs to Xellia Pharmaceuticals

    7 Jul 2020 , 12:26PM Caplin Steriles signs private label distribution agreement with xellia pharmaceuticals
  • Caplin Steriles gets USFDA nod for Phenylephrine Hydrochloride Injection USP

    12 Jun 2020 , 11:26AM Caplin Steriles, develop and files 17 ANDAs on its own and with partners, with 9 approvals so far
  • Caplin Point gets USFDA nod for Ropivacaine Hydrochloride Injection

    13 Apr 2020 , 10:14AM Caplin Steriles grants final approval from the USFDA for its ANDA
  • Caplin Steriles gets USFDA approval for Verapamil Hydrochloride Injection USP

    26 Mar 2020 , 11:15AM Caplin Point gets USFDA nod for Verapamil Hydrochloride Injection, used in treatment of high BP, Angina
  • Caplin Steriles gets USFDA approval for Sodiume Nitroprusside Injections

    3 Dec 2019 , 2:33PM Caplin Point gets final approval from the USFDA for its ANDA Sodium Nitroprusside injection
  • Caplin Point gets USFDA inspection report for injectable unit

    25 Jul 2019 , 12:23PM Receives EIR report for injectable facility
  • Caplin Steriles gets USFDA approval for Tranexamic Acid Injection

    18 Jul 2019 , 11:59AM Caplin Steriles gets USFDA approval for Tranexamic Acid Injection, a generic therapeutic equivalent version of Cyklokapron Injection
  • Caplin Point gets Colombia approval for Sterile Injectables

    13 May 2019 , 11:37AM Caplin Point receives Colombia's INVIMA approval for its small volume sterile injectable division at Puducherry
  • Caplin Point arm inks pact with Baxter Healthcare Corporation

    8 Apr 2019 , 12:55PM Caplin Steriles signs license and supply agreement with Baxter Healthcare Corporation
  • Caplin Points up after USFDA inspection

    7 Sep 2018 , 12:05PM Caplin Points rises over 4% to Rs522, after its sterile injectable site has completed the USFDA audit with no observations

Key fundamentals

Evaluate the intrinsic value of Caplin Point Laboratories Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 1390.15 1139.91 930.65 758.6853 600.1883
Liabilities 1390.15 1139.91 930.65 758.6853 600.1883
Equity 15.19 15.18 15.16 15.1286 15.1286
Gross Profit 287.08 219.92 219.62 213.9248 206.9924
Net Profit 283.71 234.26 187.87 156.2198 197.6385
Cash From Operating Activities 104.21 157.1 230.97 294.6452 87.0055
NPM(%) 45.38 44.31 35.57 32.36 37.44
Revenue 625.09 528.61 528.06 482.6796 527.8253
Expenses 338.01 308.69 308.44 268.7548 320.8329
ROE(%) 11.15 9.21 7.38 6.14 7.77

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
23 Sep 2024 2.5 125 0.27 1580.8
31 May 2024 2.5 125 0.27 1363.8
14 Sep 2023 2.5 125 0.27 896
21 Sep 2022 2 100 0.27 820.15
23 May 2022 2 100 0.27 663.3
20 Sep 2021 1.5 75 0.27 913.6
18 May 2021 1.5 75 0.27 560.3
21 Sep 2020 0.4 20 0.27 368.75
12 Mar 2020 2.1 105 0.27 299.1
04 Sep 2019 2.2 110 0.27 397.65
18 Sep 2018 2 100 0.27 595.25
07 Sep 2017 1.5 75 0.27 470.8
01 Sep 2016 3.5 35 0.27 998.85
15 Feb 2016 2.5 25 0.27 1206.8
29 Oct 2015 5 50 0.27 1364.4
11 Dec 2014 4 40 0.27 420.2

Peers

Other companies within the same industry or sector that are comparable to Caplin Point Laboratories Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 814.90 -3.22 11.50 1059.34 1321.50 1.41
Lotus Eye Hospital and Institute Ltd 74.33 -1.01 309.71 3860.11 14.01 0.67
Vaishali Pharma Ltd 11.94 -1.24 398.00 1989.65 2.76 0.00
Astec Lifesciences Ltd 666.80 -0.94 0.00 3639.75 -687.11 0.00

Company Info

The Company was incorporated on 16th April, 1990 under the Act as a Private Limited Company under the name of CAPLIN POINT LABORATORIES PRIVATE LIMITED. The name of the Company was changed to CAPLIN POINT LABORATORIES LIMITED effective 23rd April 1993. The Company has adopted a new set of Articles on 12th March, 1993 as applicable to public limited companies. The Company was incorporated as an extension of a pharmaceutical manufacturing unit started by M/s Triwin Pharmaceuticals, the first pharmaceutical venture started by Mr. P C Partheeban (presently the Managing Director), Mr. T Palanisamy and Mr. S Karunakaran in the year 1987 as a partnership firm. In the year 1990, the Company was incorporated by the partners of the aforesaid firm alongwith Mr. B A Ahmed. Soon thereafter, Mr. S Jayaraman joined the Board to take charge of production. Recently, the Board has been recast with all Directors except Mr.P.C.Partheeban making room for broadbasing the Board. The resigning Directors have taken positions as Senior level Managers in the Company. M/s Triwin Pharmaceuticals was engaged in the business of manufacture of Tablets, Liquid orals and Capsules (Non-Antibiotic) and Import Sales of family planning and certain life saving drugs. The said firm also started the Export of manufactured formulations in the year 1992-93. Even after the incorporation of the Company, the firm continued its manufacturing, sales and export of Tablets, Liquid orals and Capsules (Non-Antibiotic) and business of import sales while the Company started the manufacture of Ointments, Oral Powders and Capsules (Antibiotic). The said firm has since been taken over by the Company with effect from 1st September, 1993 with the objective of consolidation of the business of the Company into a single larger entity for setting up the Project envisaged. All the assets and liabilities of the firm were taken over at book values as at 31st August 1993. The Company's turnover in future shall comprise of the sales generated from the manufacturing faculties of the erstwhile firm also. Salient terms of the takeover Agreement executed by the Company with M/s. Triwin Pharmacuticals ('Triwin') are as follows. a. Transfer and vesting of assets and liabilities of Triwin in the Company All the assets and liabilities of Triwin including its factory located at No. 44, Kamakoti Nagar Annexe,Valasaravakkam, Madras 600 087, on going business basis are transferred at book values as on 31st August 1993. b. Net consideration for the transfer of assets and liabilities Consideration payable by the Company shall be the net worth of Triwin (excluding good will) estimated at Rs.31,62,000 on the basis of its audited accounts as at 31st August 1993. c. Continuance of Business In the post-transfer stage, the Company to continue to do the business then carried on by Triwin (including the manufacturing operation) and Triwin shall suspend all the production/sales activities hitherto carried on by them. d. Discharge of Purchase consideration The Company to issue at par its Shares credited as fully paid-up to the partners of Triwin for an aggregate nominal value of Rs. 31,62,000 (Rupees Thirty One lacs Sixty Two Thousand only) in the proportion of amounts lying to the credit of the respective capital/current accounts as on 31st August 1993. 2010 -Caplin Point Laboratories Ltd has recommended a final dividend of Re. 1/- per share (10%) 2011 -Caplin Point Laboratories Ltd has Recommended a final Dividend of Re. 1.50 per share (15%) -Mr. Vivek Siddharth has been appointed as the Chief Operating Officer of the Company 2012 -Caplin Point Laboratories Ltd has recommended dividend a final dividend of Rs. 2/- per share (20%) -Mr. D. P. Mishra has been appointed as a Whole Time Director of the Company 2013 -Mr. Mohanraj has been appointed as the Vice President - Finance and Company Secretary of the company. 2014 -Caplin has commenced its additional line of Production in the area of Suppositories which is unique in its feature which very few Pharma Companies have. -Caplin Point Lab gets listing on Forbes Asia and rsquo;s ‘200 Best Billion and rsquo; 2014. 2015 -Caplin Point Lab - Caplin Point gets EU GMP approval for Sterile Injectable Site -Caplin Point Lab - Caplin Point gets Brazil's Anvisa approval for Sterile Injectable Site 2016 -Caplin Point Lab - US FDA inspection completed at Caplin Point's Injectable site. 2017 -Caplin Point Laboratories received approval from the U.S. Food and Drug Administration (USFDA) of its Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection 30mg/mL, a product developed for Cycle Pharmaceuticals. -Caplin Point gets USFDA nod for Ketorolac Tromethamine Injection. 2018 -USFDA completes inspection at Caplin Point Lab's sterile injectable facility in Tamil Nadu. 2019 -Caplin Point Laboratories partners with Baxter Corporation for injectable portfolio. -USFDA completes inspection at Caplin Steriles Injectable site. -Caplin Steriles gets USFDA nod for hemorrhage prevention drug. -Caplin Point Labs gets EIR from USFDA for injectable facility. 2020 -Caplin Point Laboratories Chairman C C Paarthipan said the company has partnered with Xellia which has a long standing track record of commercial success in the US for injectable products. -Caplin Point Laboratories received the final approval from the US drug regulator for its Abbreviated New Drug Application (ANDA) Phenylephrine Hydrochloride injection. -Caplin Point Laboratories Ltd -Caplin Steriles Gets USFDA Approval For Verapamil Hydrochloride Injection USP 2021 -Caplin Point arm inks strategic partnership with Canada's JAMP Pharma Group. -Caplin Point Laboratories arm gets USFDA nod for Neostigmine Methylsulfate Injection. 2023 - Lifetime Achievement Award 2023-Business - Forbes Asia Best Under Billion Award 2023

The Company was incorporated on 16th April, 1990 under the Act as a Private Limited Company under the name of CAPLIN POINT LABORATORIES PRIVATE LIMITED. The name of the Company was changed to CAPLIN POINT LABORATORIES LIMITED effective 23rd April 1993. The Company has adopted a new set of Articles on 12th March, 1993 as applicable to public limited companies. The Company was incorporated as an extension of a pharmaceutical manufacturing unit started by M/s Triwin Pharmaceuticals, the first pharmaceutical venture started by Mr. P C Partheeban (presently the Managing Director), Mr. T Palanisamy and Mr. S Karunakaran in the year 1987 as a partnership firm. In the year 1990, the Company was incorporated by the partners of the aforesaid firm alongwith Mr. B A Ahmed. Soon thereafter, Mr. S Jayaraman joined the Board to take charge of production. Recently, the Board has been recast with all Directors except Mr.P.C.Partheeban making room for broadbasing the Board. The resigning Directors have taken positions as Senior level Managers in the Company. M/s Triwin Pharmaceuticals was engaged in the business of manufacture of Tablets, Liquid orals and Capsules (Non-Antibiotic) and Import Sales of family planning and certain life saving drugs. The said firm also started the Export of manufactured formulations in the year 1992-93. Even after the incorporation of the Company, the firm continued its manufacturing, sales and export of Tablets, Liquid orals and Capsules (Non-Antibiotic) and business of import sales while the Company started the manufacture of Ointments, Oral Powders and Capsules (Antibiotic). The said firm has since been taken over by the Company with effect from 1st September, 1993 with the objective of consolidation of the business of the Company into a single larger entity for setting up the Project envisaged. All the assets and liabilities of the firm were taken over at book values as at 31st August 1993. The Company's turnover in future shall comprise of the sales generated from the manufacturing faculties of the erstwhile firm also. Salient terms of the takeover Agreement executed by the Company with M/s. Triwin Pharmacuticals ('Triwin') are as follows. a. Transfer and vesting of assets and liabilities of Triwin in the Company All the assets and liabilities of Triwin including its factory located at No. 44, Kamakoti Nagar Annexe,Valasaravakkam, Madras 600 087, on going business basis are transferred at book values as on 31st August 1993. b. Net consideration for the transfer of assets and liabilities Consideration payable by the Company shall be the net worth of Triwin (excluding good will) estimated at Rs.31,62,000 on the basis of its audited accounts as at 31st August 1993. c. Continuance of Business In the post-transfer stage, the Company to continue to do the business then carried on by Triwin (including the manufacturing operation) and Triwin shall suspend all the production/sales activities hitherto carried on by them. d. Discharge of Purchase consideration The Company to issue at par its Shares credited as fully paid-up to the partners of Triwin for an aggregate nominal value of Rs. 31,62,000 (Rupees Thirty One lacs Sixty Two Thousand only) in the proportion of amounts lying to the credit of the respective capital/current accounts as on 31st August 1993. 2010 -Caplin Point Laboratories Ltd has recommended a final dividend of Re. 1/- per share (10%) 2011 -Caplin Point Laboratories Ltd has Recommended a final Dividend of Re. 1.50 per share (15%) -Mr. Vivek Siddharth has been appointed as the Chief Operating Officer of the Company 2012 -Caplin Point Laboratories Ltd has recommended dividend a final dividend of Rs. 2/- per share (20%) -Mr. D. P. Mishra has been appointed as a Whole Time Director of the Company 2013 -Mr. Mohanraj has been appointed as the Vice President - Finance and Company Secretary of the company. 2014 -Caplin has commenced its additional line of Production in the area of Suppositories which is unique in its feature which very few Pharma Companies have. -Caplin Point Lab gets listing on Forbes Asia and rsquo;s ‘200 Best Billion and rsquo; 2014. 2015 -Caplin Point Lab - Caplin Point gets EU GMP approval for Sterile Injectable Site -Caplin Point Lab - Caplin Point gets Brazil's Anvisa approval for Sterile Injectable Site 2016 -Caplin Point Lab - US FDA inspection completed at Caplin Point's Injectable site. 2017 -Caplin Point Laboratories received approval from the U.S. Food and Drug Administration (USFDA) of its Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection 30mg/mL, a product developed for Cycle Pharmaceuticals. -Caplin Point gets USFDA nod for Ketorolac Tromethamine Injection. 2018 -USFDA completes inspection at Caplin Point Lab's sterile injectable facility in Tamil Nadu. 2019 -Caplin Point Laboratories partners with Baxter Corporation for injectable portfolio. -USFDA completes inspection at Caplin Steriles Injectable site. -Caplin Steriles gets USFDA nod for hemorrhage prevention drug. -Caplin Point Labs gets EIR from USFDA for injectable facility. 2020 -Caplin Point Laboratories Chairman C C Paarthipan said the company has partnered with Xellia which has a long standing track record of commercial success in the US for injectable products. -Caplin Point Laboratories received the final approval from the US drug regulator for its Abbreviated New Drug Application (ANDA) Phenylephrine Hydrochloride injection. -Caplin Point Laboratories Ltd -Caplin Steriles Gets USFDA Approval For Verapamil Hydrochloride Injection USP 2021 -Caplin Point arm inks strategic partnership with Canada's JAMP Pharma Group. -Caplin Point Laboratories arm gets USFDA nod for Neostigmine Methylsulfate Injection. 2023 - Lifetime Achievement Award 2023-Business - Forbes Asia Best Under Billion Award 2023

Read More

Parent Organisation

Caplin Point Laboratories Ltd.

Founded

16/04/1990

Managing Director

Dr.Sridhar Ganesan

NSE Symbol

CAPLIPOINTEQ

FAQ

The current price of Caplin Point Laboratories Ltd is ₹ 1852.70.

The 52-week high for Caplin Point Laboratories Ltd is ₹ 1902.40 and the 52-week low is ₹ 1830.10.

The market capitalization of Caplin Point Laboratories Ltd is currently ₹ 14082.69. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Caplin Point Laboratories Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Caplin Point Laboratories Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Caplin Point Laboratories Ltd shares.

The CEO of Caplin Point Laboratories Ltd is Dr.Sridhar Ganesan, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT